Catalent, Inc. (NYSE:CTLT) Shares Acquired by Creative Planning

Creative Planning lifted its position in shares of Catalent, Inc. (NYSE:CTLT) by 21.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,935 shares of the company’s stock after acquiring an additional 1,222 shares during the quarter. Creative Planning’s holdings in Catalent were worth $420,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CTLT. Millennium Management LLC boosted its holdings in Catalent by 129.2% during the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after buying an additional 2,299,784 shares in the last quarter. Magnetar Financial LLC purchased a new stake in Catalent during the first quarter worth about $56,429,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Catalent during the second quarter worth about $29,172,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Catalent by 2,792.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock valued at $29,150,000 after purchasing an additional 498,540 shares in the last quarter. Finally, Bank of Montreal Can lifted its holdings in shares of Catalent by 222.0% in the second quarter. Bank of Montreal Can now owns 644,123 shares of the company’s stock valued at $36,219,000 after purchasing an additional 444,084 shares in the last quarter.

Catalent Price Performance

Catalent stock opened at $59.89 on Friday. Catalent, Inc. has a 52-week low of $32.38 and a 52-week high of $61.20. The firm has a fifty day moving average of $60.01 and a 200-day moving average of $58.05. The firm has a market capitalization of $10.87 billion, a P/E ratio of -10.91, a PEG ratio of 2.06 and a beta of 1.16. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the company earned ($0.10) EPS. Catalent’s revenue was up 4.2% on a year-over-year basis. As a group, analysts predict that Catalent, Inc. will post 0.95 EPS for the current year.

Insider Activity at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

CTLT has been the topic of several recent research reports. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a report on Wednesday. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. One analyst has rated the stock with a sell rating and eight have given a hold rating to the stock. Based on data from MarketBeat, Catalent has a consensus rating of “Hold” and a consensus price target of $59.83.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.